MeiraGTx Holdings plc (MGTX )

Currency in USD Disclaimer
$5.33 +$0.69 (14.87%)
Closed 10/15/2024
$4.84
$5.87
$3.49
$7.6

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol MGTX
  • Company MeiraGTx Holdings plc
  • Price $5.33
  • Changes Percentage 14.87
  • Change 0.69
  • Day Low $4.84
  • Day High $5.87
  • Year High $7.6
  • Year Low $3.49
  • Market Cap $412,536,137
  • Price Avg 50 EMA (D) $4.17
  • Price Avg 200 EMA (D) $5.18
  • Exchange NASDAQ
  • Volume 2,035,596
  • Average Volume 186,759
  • Open $5.85
  • Previous Close $4.64
  • EPS -1.42
  • PE -3.75
  • Earnings Announcement 2024-11-12 13:30:00
  • Shares Outstanding $77,398,900

Company brief: MEIRAGTX HOLDINGS PLC (MGTX )

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.

MGTX Corporation News

MeiraGTx: Positive PD Data Moves Needle Forward For Regulatory Meetings

MeiraGTx: Positive PD Data Moves Needle Forward For Regulatory Meetings

October 15, 2024 at 1:32 pm ET

seekingalpha.com -- MeiraGTx Holdings plc's GAD gene therapy for Parkinson's Disease shows promising phase 1/2 results, with significant improvements in UPDRS Part 3 and PDQ-39 scores. The company plans to discuss phase ...

Income Statement